Gilead Sciences, Inc.GILD

NasdaqGS•Healthcare•Drug Manufacturers - General

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Price & Volume

Key Metrics at a Glance (as of December 2025)

Market Cap: $154.34B
TTM Revenue: $29.44B
TTM EBITDA: $12.90B
P/E Ratio: 18.1x
Operating Margin: 37.4%
Free Cash Flow: $3.33B

Financial Analysis

Gilead Sciences, Inc. (GILD) reported trailing twelve months (TTM) revenue of $29.44B as of December 2025, which represents a 2.4% increase year-over-year. The company's operating margin has expanded to 37.4% from 32.4% a year ago. In terms of profitability, GILD generated $8.51B in net income. Valuation-wise, the stock trades at a P/E ratio of 18.1x and a Price-to-Sales (P/S) ratio of 5.2x. The company generated $3.33B in free cash flow over the last twelve months, indicating its ability to reinvest in growth or return capital to shareholders. Data based on the most recent quarterly reports.